Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).

Humans Administration, Intravesical BCG Vaccine / therapeutic use Docetaxel / therapeutic use Gemcitabine Non-Muscle Invasive Bladder Neoplasms Urinary Bladder Neoplasms / drug therapy Randomized Controlled Trials as Topic Clinical Trials, Phase III as Topic

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
07 2023
Historique:
received: 20 04 2023
revised: 12 05 2023
accepted: 15 06 2023
pmc-release: 06 07 2024
medline: 31 7 2023
pubmed: 9 7 2023
entrez: 8 7 2023
Statut: ppublish

Résumé

EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.

Identifiants

DOI: 10.1016/j.euf.2023.06.006 PMID: 37422371 PMC: PMC10515442
pubmed: 37422371
pii: S2405-4569(23)00146-3
doi: 10.1016/j.euf.2023.06.006
pmc: PMC10515442
mid: NIHMS1931295
pii:
doi:

Substances chimiques

BCG Vaccine 0
Docetaxel 15H5577CQD
Gemcitabine 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

561-563

Subventions

Organisme : NCI NIH HHS
ID : UG1 CA233290
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA180830
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180830
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233373
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233196
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180794
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189854
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Références

J Urol. 2020 May;203(5):902-909
pubmed: 31821066
J Urol. 2013 Sep;190(3):857-62
pubmed: 23545101
J Urol. 2022 Sep;208(3):589-599
pubmed: 35892270
J Urol. 2021 Jun;205(6):1612-1621
pubmed: 33502236
J Urol. 2013 Mar;189(3):834-9
pubmed: 23123371
Urol Oncol. 2020 Nov;38(11):851.e11-851.e17
pubmed: 32800440
J Clin Oncol. 2016 Jun 1;34(16):1935-44
pubmed: 26811532
Eur Urol. 2020 Nov;78(5):690-698
pubmed: 32446864
Cancer. 2010 Apr 15;116(8):1893-900
pubmed: 20162706

Auteurs

Max Kates (M)

Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. Electronic address: mkates@jhmi.edu.

Xiangying Chu (X)

Department of Biostatistics, School of Medicine, Harvard University, Boston, MA, USA.

Noah Hahn (N)

Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

Eugene Pietzak (E)

Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Angela Smith (A)

Department of Urology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Daniel H Shevrin (DH)

Northshore Medical Group, Glenview, IL, USA.

Paul Crispen (P)

Department of Urology, University of Florida School of Medicine, Gainesville, FL, USA.

Stephen B Williams (SB)

Division of Urology, University of Texas Medical Branch, Galveston, TX, USA.

Siamak Daneshmand (S)

Catherine and Joseph Aresty Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Vignesh T Packiam (VT)

Department of Urology, University of Iowa, Iowa City, IA, USA.

Sima Porten (S)

Department of Urology, UCSF School of Medicine, San Francisco, CA, USA.

Mary E Westerman (ME)

Department of Urology, LSU Health Science Center, New Orleans, LA, USA.

Lynne I Wagner (LI)

Department of Social Sciences and Health Policy, School of Medicine, Wake Forest University, Winston-Salem, NC, USA.

Michael Carducci (M)

Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie topique › Administration par voie vésicale › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antibactériens › Vaccins antituberculeux › Vaccin BCG › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Docetaxel › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Gemcitabine › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs de la vessie urinaire › Tumeurs de la vessie n'infiltrant pas le muscle › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs de la vessie urinaire › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Background and Update for ECOG-ACRIN EA8212: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques de phase III comme sujet › Background and Update for ECOG-ACRIN EA8212: A...